Sunesis Pharmaceuticals (SNSS) has reported its Q4 and 2012 results. For the quarter, revenue was just under $2 million. Comprehensive net loss narrowed to $4 million ($0.20 per diluted share) from Q4 2011's red figure of $8.7 million ($0.19). The company did not report any revenue for the latter period.
Analysts had expected revenue of $400,000 and a per-share loss of $0.19 for the most recent quarter.
For the full year, top line was $3.8 million, notably lower than the 2011 figure of $5 million. Comprehensive net loss widened considerably, landing at almost $44 million ($0.91 per diluted share) for the year against 2011's shortfall of $20 million ($0.43).
